Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Crescent Biopharma, Inc. has 5 disclosed suppliers and 1 disclosed customer. Each one is named in an SEC filing, either Crescent Biopharma, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“Under the Charles River MSA, we are obligated to pay Charles River a service fee in the amount specified in each Statement of Work associated with the agreement for the provision of services.”
FILING10-K0001628280-26-011983cik 0001253689
“We have and may continue to utilize Paragon Therapeutics, Inc. ("Paragon") to conduct certain research activities (primarily preclinical studies) pursuant to discovery and option agreements into which we may enter, such as the Antibody Discovery and Option Agreement, dated September 19, 2024 (the "Antibody Paragon Option Agreement"), by and among Crescent, Paragon, and Parascent Holding LLC.”
FILING10-K0001628280-26-011983cik 0001253689
“Under the WuXi Biologics MSA, we are obligated to pay WuXi Biologics (Hong Kong) a service fee and all non-cancellable obligations in the amount specified in each work order associated with the agreement for the provision of services.”
FILING10-K0001628280-26-011983cik 0001253689
“Under the Cell Line License Agreement, we received a non-exclusive, worldwide, sublicensable license to certain of WuXi Biologics Ireland's know-how, cell line, biological materials and media and feeds to make, have made, use, sell, have sold, offer for sale, import, keep and otherwise deal in and further commercialize certain therapeutic products produced through the use of the cell line licensed by WuXi Biologics Ireland under the Cell Line License Agreement (the "WuXi Biologics Ireland Licensed Products").”
FILING10-K0001628280-26-011983cik 0001253689
“On December 2, 2025, we entered into a License Agreement (the "Kelun CR-001 License Agreement") with Kelun under which we granted Kelun an exclusive, royalty-bearing license to research, develop, manufacture and commercialize CR-001, our proprietary bispecific antibody directed to VEGF and PD-1, in Greater China (the "SKB Territory").”
FILING10-K0001628280-26-011983cik 0001253689
“While we do not currently solely own any patents or patent applications, we in-license certain patent rights from Paragon pursuant to those certain License Agreements, dated each of April 28, 2025 (the "CR-001 License Agreement") and November 5, 2025 (the "CR-002 License Agreement"), each by and between us and Paragon (collectively, the "Paragon License Agreements") relating to certain of our product candidates, and patent rights from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun") pursuant to that certain License and Collaboration Agreement, dated December 2, 2025, by and between us and Kelun relating to CR-003 outside of mainland China, Hong Kong, Macau and Taiwan.”
FILING10-K0001628280-26-011983cik 0001253689
Watchlist prices, news filtered to it, and its next report on your desk.
Crescent Biopharma, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Prev close 18.86 · gapped above the open, then crossed back over prior close. High/low 19.21 at 9:45 am ET, 18.52 at 11:15 am ET.
CBIO (Crescent Biopharma, Inc.) has 5 disclosed suppliers and 1 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: CRL +0.14%, in healthcare.